Sareum Holdings PLC Appointment of Sole Broker
30 May 2024 - 4:00PM
RNS Regulatory News
RNS Number : 3560Q
Sareum Holdings PLC
30 May 2024
Sareum Holdings plc
("Sareum" or the "Company")
Appointment of Sole Broker
Cambridge, UK, 30 May 2024 -
Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology
company developing next-generation kinase inhibitors for autoimmune
disease and cancer, announces that Hybridan LLP is now acting as
the Company's sole broker with immediate effect.
- END -
For Further
Information:
|
Sareum
Holdings plc
Tim Mitchell, CEO
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson
Limited (Nominated Adviser)
James Dance / James Bellman
|
020 7409
3494
|
|
Hybridan LLP
(Corporate Broker)
Claire Noyce
|
020 3764
2341
|
|
ICR Consilium
(Financial PR)
Jessica Hodgson / Davide Salvi / Kumail Waljee
|
0203 709
5700
|
About
Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage
biotechnology company developing next generation kinase inhibitors
for autoimmune disease and cancer.
The Company is focused on developing next
generation small molecules which modify the activity of the JAK
kinase family and have best-in-class potential. Its lead candidate,
SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a
potential treatment for a range of autoimmune diseases and has
entered Phase 1a/b clinical development with an initial focus on
psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1
inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in Cambridge, UK,
and is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit
the Company's website at www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPVKLFLZELEBBZ
Sareum (LSE:SAR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Sareum (LSE:SAR)
Historical Stock Chart
From Jan 2024 to Jan 2025
